Bahram (Bob) Valamehr is President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations, including overseeing the company’s research and development, technical operations and translational sciences activities. Previously, Dr. Valamehr led the development of Fate’s iPSC platform and therapeutic areas for nearly 15 years and most recently held the role of President of R&D. Prior to joining Fate, Dr. Valamehr played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with aberrant cellular function. He has co-authored numerous studies and patents related to stem cell biology, immunology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.
